Characterization of the skeletal muscle arginine methylome in health and disease reveals remodeling in amyotrophic lateral sclerosis

Julian P.H. Wong, Ronnie Blazev, Yaan Kit Ng, Craig A. Goodman, Magdalene K. Montgomery, Kevin I. Watt, Christian S. Carl, Matthew J. Watt, Christian T. Voldstedlund, Erik A. Richter, Peter J. Crouch, Frederik J. Steyn, Shyuan T. Ngo, Benjamin L. Parker*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Arginine methylation is a protein posttranslational modification important for the development of skeletal muscle mass and function. Despite this, our understanding of the regulation of arginine methylation under settings of health and disease remains largely undefined. Here, we investigated the regulation of arginine methylation in skeletal muscles in response to exercise and hypertrophic growth, and in diseases involving metabolic dysfunction and atrophy. We report a limited regulation of arginine methylation under physiological settings that promote muscle health, such as during growth and acute exercise, nor in disease models of insulin resistance. In contrast, we saw a significant remodeling of asymmetric dimethylation in models of atrophy characterized by the loss of innervation, including in muscle biopsies from patients with myotrophic lateral sclerosis (ALS). Mass spectrometry-based quantification of the proteome and asymmetric arginine dimethylome of skeletal muscle from individuals with ALS revealed the largest compendium of protein changes with the identification of 793 regulated proteins, and novel site-specific changes in asymmetric dimethyl arginine (aDMA) of key sarcomeric and cytoskeletal proteins. Finally, we show that in vivo overexpression of PRMT1 and aDMA resulted in increased fatigue resistance and functional recovery in mice. Our study provides evidence for asymmetric dimethylation as a regulator of muscle pathophysiology and presents a valuable proteomics resource and rationale for numerous methylated and nonmethylated proteins, including PRMT1, to be pursued for therapeutic development in ALS.

Original languageEnglish
Article numbere23647
JournalFASEB Journal
Volume38
Issue number10
ISSN0892-6638
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 Federation of American Societies for Experimental Biology.

Keywords

  • amyotrophic lateral sclerosis
  • arginine dimethylation
  • arginine methylation
  • proteomics
  • skeletal muscle

Cite this